683 Capital Management’s scPharmaceuticals SCPH Stock Holding History

683 Capital Management’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,000	Closed	-$190K	–	237
2023 Q1	$190K	Sell	21,000 -5,424	-21%	-$39.7K	0.01%	161
2022 Q4	$189K	Buy	+26,424	New	+$161K	0.02%	179

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

683 Capital Management's SCPH Position: Q2 2023 in Review

683 Capital Management sold out of scPharmaceuticals (SCPH) in Q2 2023, closing a stake of 21,000 shares — an estimated $190K sold.

683 Capital Management first reported a position in SCPH in Q4 2022 and held it in 2 quarters. The position peaked at $190K in Q1 2023. 81 funds tracked by Wall St. Rank hold SCPH as of Q2 2023.

683 Capital Management reported no remaining scPharmaceuticals position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 21,000 scPharmaceuticals shares in Q2 2023, an estimated $190K.
683 Capital Management first reported a position in scPharmaceuticals in Q4 2022 and held it in 2 quarters.
683 Capital Management's scPharmaceuticals position peaked at $190K in Q1 2023.
81 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.